Mirum reports four positive readouts, raises 2026 sales guidance to $715M-$720MNov 3Quarterly updatebulevirtidemaralixibat
Mirum reports positive Phase 3 EXPAND data for Livmarli in cholestatic liver diseasesOct 13Clinical readoutmaralixibatMirum Pharmaceuticals, Inc.
Mirum registers Phase 2 trial of maralixibat for cholestasis of pregnancySep 16Trial updatemaralixibatMirum Pharmaceuticals, Inc.
Mirum raises 2026 sales guidance, volixibat gets FDA breakthrough status for PSCAug 5Quarterly updateMirum Pharmaceuticals, Inc.volixibat